From a clinical perspective, these results suggest that, in gBRCApv, monitoring AMH changes during NAC (from baseline to Mid-CT) using a hypersensitive assay could provide early information on the response of BRCA-deficient breast cancer cells to the anthracycline regimen. The gene discussed is AMH; the disease is breast carcinoma.